GlassScriptPhysician profile
Farris Burns
NPI 1942750187
$5,308.25
in general payments reported to CMS, 2019-2025
30 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $866 · 2023: $1,153 · 2024: $1,203 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,682.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $659.46 | 2021-2025 | |
| Novo Nordisk INC | $634.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $601.11 | 2021-2025 | |
| Lilly USA, LLC | $501.78 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $481.74 | 2021-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $461.94 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.03 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.24 | 2021-2024 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $256.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $164.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $141.87 | 2022 | |
| Xeris Pharmaceuticals, INC. | $126.88 | 2021-2025 | Keveyis |
| E.R. Squibb & Sons, L.L.C. | $124.53 | 2021-2023 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $115.18 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $91.49 | 2021-2025 | Airsupra, Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $61.30 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $43.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $41.87 | 2022-2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $35.14 | 2025 | Voquezna |
| Lundbeck LLC | $34.72 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $28.77 | 2023-2024 | Linzess |
| Ardelyx, INC. | $27.71 | 2025 | Ibsrela |
| Abbott Laboratories | $20.13 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $19.60 | 2024 | Veozah |
| Genentech USA, INC. | $17.86 | 2021 | |
| Dexcom, INC. | $15.29 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $14.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.70 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.57 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farris Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.